Revenue growth remains stagnant at 1.2% in 2026Q1, while gross margins have experienced significant contraction from a 35.9% peak in 2023Q4 to 28.0% in the most recent period.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 |
|---|
| Sales/Revenue | 4.03B | 4.02B | 4.05B | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B | 1.36B | 1.3B | 1.17B | 1.13B | 1.14B | 1.13B | 1.2B | 1.34B | 1.23B | 1.06B | 1.12B | 766.92M | 613.72M | 554.63M | 465.63M | 306.58M | 219.28M | 193.3M |
| Revenue Growth % | 0.11% | -0.85% | -1.92% | 3.86% | 12.31% | 21.08% | 11.55% | 15.67% | 21.99% | 10.48% | 23.34% | 5.06% | 11.34% | 3.19% | -1.15% | 0.81% | -5.75% | -10.49% | 9.17% | 16.27% | -5.69% | 46.33% | 24.96% | 10.65% | 19.11% | 51.88% | 39.82% | 13.44% | - |
| Cost of Goods Sold | 2.74B | 2.79B | 2.72B | 2.63B | 2.51B | 2.21B | 1.85B | 1.66B | 1.43B | 1.16B | 1.04B | 832.21M | 825M | 770.63M | 737.45M | 740.4M | 748.66M | 748.65M | 832.78M | 752.43M | 651.78M | 603.62M | 435.5M | 380.06M | 345.65M | 298.38M | 186.65M | 146.73M | 122.55M |
| COGS % of Revenue | - | 69.48% | 67.12% | 63.61% | 63.21% | 62.3% | 63.28% | 63.44% | 62.93% | 62.27% | 61.7% | 61.04% | 63.58% | 66.12% | 65.29% | 64.8% | 66.05% | 62.26% | 61.99% | 61.14% | 61.58% | 53.79% | 56.79% | 61.93% | 62.32% | 64.08% | 60.88% | 66.92% | 63.4% |
| Gross Profit | 1.28B | 1.23B | 1.33B | 1.5B | 1.46B | 1.33B | 1.07B | 958.31M | 840.07M | 700.92M | 643.96M | 531.09M | 472.66M | 394.9M | 392.08M | 402.24M | 384.76M | 422.99M | 510.71M | 478.19M | 406.61M | 389.7M | 288.72M | 233.66M | 208.98M | 167.25M | 119.93M | 84.68M | 70.75M |
| Gross Margin % | 31.86% | 30.52% | 32.88% | 36.39% | 36.79% | 37.7% | 36.72% | 36.56% | 37.07% | 37.73% | 38.3% | 38.96% | 36.42% | 33.88% | 34.71% | 35.2% | 33.95% | 35.17% | 38.01% | 38.86% | 38.42% | 34.73% | 37.65% | 38.07% | 37.68% | 35.92% | 39.12% | 38.62% | 36.6% |
| Gross Profit Growth % | - | -7.98% | -11.36% | 2.73% | 9.59% | 24.32% | 12.02% | 14.08% | 19.85% | 8.85% | 21.25% | 12.36% | 19.69% | 0.72% | -2.53% | 4.54% | -9.04% | -17.18% | 6.8% | 17.61% | 4.34% | 34.98% | 23.56% | 11.81% | 24.95% | 39.46% | 41.62% | 19.69% | - |
| Operating Expenses | 808.98M | 717.73M | 1.1B | 885.29M | 811.68M | 744.78M | 640.81M | 607.16M | 508.68M | 412.64M | 406.41M | 324.64M | 294.99M | 243.5M | 226.32M | 227.94M | 683.27M | 253.38M | 960.47M | 251M | 218.43M | 205.01M | 130.74M | 95.11M | 86.72M | 76.97M | 54.87M | 41.72M | 35.43M |
| OpEx % of Revenue | - | 17.87% | 27.27% | 21.44% | 20.41% | 21.04% | 21.92% | 23.16% | 22.45% | 22.21% | 24.17% | 23.81% | 22.73% | 20.89% | 20.04% | 19.95% | 60.28% | 21.07% | 71.49% | 20.4% | 20.64% | 18.27% | 17.05% | 15.5% | 15.64% | 16.53% | 17.9% | 19.03% | 18.33% |
| Selling, General & Admin | 716.2M | 743.07M | 751M | 747.86M | 665.1M | 619.92M | 528.93M | 517.62M | 443.85M | 371.27M | 364.71M | 300.41M | 269.03M | 225.69M | 208.25M | 198.65M | 232.49M | 227.66M | 230.16M | 217.49M | 180.79M | 158M | 116.88M | 90.24M | 83.3M | 68.31M | 51.2M | 39.77M | 34.14M |
| SG&A % of Revenue | - | 18.51% | 18.54% | 18.11% | 16.73% | 17.51% | 18.09% | 19.75% | 19.59% | 19.99% | 21.69% | 22.04% | 20.73% | 19.36% | 18.44% | 17.38% | 20.51% | 18.93% | 17.13% | 17.67% | 17.08% | 14.08% | 15.24% | 14.7% | 15.02% | 14.67% | 16.7% | 18.13% | 17.66% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 2M | -25.34M | 353.47M | 137.44M | 146.58M | 124.86M | 111.88M | 89.54M | 64.83M | 41.37M | 41.7M | 24.23M | 25.96M | 17.81M | 18.07M | 29.29M | 450.78M | 25.72M | 730.31M | 33.51M | 37.64M | 47.01M | 13.86M | 4.88M | 3.41M | 8.65M | 3.67M | 1.96M | 1.29M |
| Operating Income | 474.05M | 507.84M | 227.35M | 617.26M | 650.98M | 589.86M | 432.73M | 351.15M | 331.38M | 288.28M | 237.55M | 206.45M | 177.67M | 151.4M | 165.76M | 174.31M | -298.51M | 169.61M | -449.76M | 227.19M | 188.17M | 184.69M | 157.99M | 138.55M | 122.27M | 90.28M | 65.06M | 42.96M | 35.33M |
| Operating Margin % | 11.77% | 12.65% | 5.61% | 14.95% | 16.37% | 16.66% | 14.8% | 13.4% | 14.62% | 15.52% | 14.13% | 15.14% | 13.69% | 12.99% | 14.68% | 15.25% | -26.34% | 14.1% | -33.48% | 18.46% | 17.78% | 16.46% | 20.6% | 22.58% | 22.04% | 19.39% | 21.22% | 19.59% | 18.27% |
| Operating Income Growth % | - | 123.38% | -63.17% | -5.18% | 10.36% | 36.31% | 23.23% | 5.97% | 14.95% | 21.36% | 15.07% | 16.2% | 17.35% | -8.67% | -4.9% | 158.39% | -276% | 137.71% | -297.97% | 20.74% | 1.88% | 16.91% | 14.03% | 13.32% | 35.43% | 38.77% | 51.43% | 21.62% | - |
| EBITDA | 824.15M | 911.15M | 589.09M | 931.38M | 954.85M | 855.4M | 667.65M | 549.25M | 493.16M | 419.44M | 364.21M | 301.33M | 274.12M | 248.04M | 247.04M | 259.54M | -204.86M | 259.57M | -358.58M | 313.57M | 273.3M | 274.81M | 201.92M | 169.67M | 147.99M | 118.86M | 83.93M | 58.61M | 46.22M |
| EBITDA Margin % | 20.47% | 22.69% | 14.55% | 22.55% | 24.01% | 24.16% | 22.83% | 20.95% | 21.76% | 22.58% | 21.66% | 22.1% | 21.12% | 21.28% | 21.87% | 22.71% | -18.07% | 21.59% | -26.69% | 25.48% | 25.82% | 24.49% | 26.33% | 27.65% | 26.68% | 25.53% | 27.38% | 26.73% | 23.91% |
| EBITDA Growth % | 43.88% | 54.67% | -36.75% | -2.46% | 11.63% | 28.12% | 21.56% | 11.37% | 17.58% | 15.16% | 20.87% | 9.93% | 10.51% | 0.4% | -4.81% | 226.69% | -178.92% | 172.39% | -214.35% | 14.73% | -0.55% | 36.1% | 19% | 14.65% | 24.51% | 41.62% | 43.21% | 26.8% | - |
| D&A (Non-Cash Add-back) | 350.1M | 403.31M | 361.74M | 314.12M | 303.87M | 265.54M | 234.92M | 198.09M | 161.78M | 131.16M | 126.66M | 94.88M | 96.44M | 96.64M | 81.28M | 85.23M | 93.65M | 89.96M | 91.18M | 86.38M | 85.13M | 90.12M | 43.93M | 31.12M | 25.73M | 28.58M | 18.87M | 15.64M | 10.89M |
| EBIT | 454.11M | 507.84M | 219.4M | 717.99M | 682.28M | 554.62M | 533.55M | 364.97M | 345.45M | 326.73M | 250.63M | 210.5M | 189.54M | 159.3M | 163.09M | 175.25M | -298.8M | 173.24M | -447M | 235.43M | 188.17M | 184.69M | 157.99M | 138.55M | 122.27M | 90.28M | 65.06M | 42.96M | 35.33M |
| Net Interest Income | -101.32M | -102.09M | -117.71M | -131.51M | -58.51M | -73.26M | -85.6M | -59.36M | -62.96M | -29.09M | -26.39M | -14.03M | -10.8M | -20.24M | -32.75M | -41.23M | -34.09M | -19.97M | -5.32M | -8.32M | -186.4M | -18.69M | -5.37M | 0 | -25.22M | -25.79M | 0 | 0 | 0 |
| Interest Income | 4.57M | 4.94M | 8.57M | 5.2M | 780K | 652K | 834K | 1.52M | 812K | 690K | 1.31M | 1.04M | 1.15M | 730K | 589K | 0 | 0 | 1.78M | 8.69M | 9.68M | 6.84M | 3.93M | 3.29M | 0 | 2.12M | 1.49M | 0 | 0 | 0 |
| Interest Expense | 105.89M | 107.03M | 126.29M | 136.71M | 59.29M | 73.91M | 86.43M | 60.88M | 63.77M | 29.78M | 27.71M | 15.07M | 11.95M | 20.97M | 33.34M | 41.23M | 34.09M | 21.68M | 14.01M | 14.83M | 193.24M | 22.62M | 8.65M | 6.56M | 27.34M | 27.28M | 67.35M | 8.28M | 0 |
| Other Income/Expense | -639.47M | -607.34M | -134.23M | -35.98M | -27.99M | -109.15M | 14.38M | -47.07M | -49.7M | 8.67M | -14.63M | -11.02M | -75K | -13.07M | -36.02M | -41.64M | -35.57M | -18.06M | -11.25M | -9.77M | -11.61M | -20.81M | -7.52M | -5.92M | -37.74M | -30.6M | -39.35M | -12.3M | 507K |
| Pretax Income | -165.42M | -99.5M | 93.11M | 581.28M | 622.99M | 480.71M | 447.11M | 304.08M | 281.68M | 296.95M | 222.92M | 195.43M | 177.59M | 138.33M | 129.75M | 132.66M | -334.08M | 149.11M | -461.01M | 217.42M | 176.56M | 160.41M | 152.53M | 132.63M | 114.4M | 69.48M | 25.71M | 32.69M | 35.83M |
| Pretax Margin % | -4.11% | -2.48% | 2.3% | 14.08% | 15.67% | 13.58% | 15.29% | 11.6% | 12.43% | 15.99% | 13.26% | 14.33% | 13.69% | 11.87% | 11.49% | 11.61% | -29.48% | 12.4% | -34.31% | 17.67% | 16.68% | 14.29% | 19.89% | 21.61% | 20.63% | 14.92% | 8.39% | 14.91% | 18.54% |
| Income Tax | 17.42M | 42.66M | 67.82M | 100.91M | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M | 171.37M | 66.83M | 43.39M | 47.67M | 32.91M | 27.63M | 17.14M | 23K | 39.73M | 61.94M | 59.4M | 49.74M | 16.58M | 61.16M | 51.06M | 43.57M | 27.09M | 7.84M | 15.56M | 14.12M |
| Effective Tax Rate % | -10.53% | -42.87% | 72.84% | 17.36% | 20.93% | 17.03% | 18.3% | 16.45% | 19.33% | 57.71% | 29.98% | 22.2% | 26.84% | 23.79% | 21.29% | 12.92% | -0.01% | 26.64% | -13.44% | 27.32% | 28.17% | 10.33% | 40.1% | 38.5% | 38.09% | 39% | 30.48% | 47.61% | 39.41% |
| Net Income | -184.65M | -144.34M | 10.3M | 474.62M | 486.23M | 390.98M | 364.3M | 252.02M | 226.37M | 123.36M | 154.76M | 149.31M | 126.7M | 102.83M | 97.3M | 109.57M | -336.67M | 114.44M | -521.84M | 154.41M | -55.78M | 142M | 89.79M | 80.15M | 50.13M | 35.41M | -11.22M | 17.12M | 23.38M |
| Net Margin % | -4.59% | -3.59% | 0.25% | 11.49% | 12.23% | 11.04% | 12.46% | 9.61% | 9.99% | 6.64% | 9.2% | 10.95% | 9.76% | 8.82% | 8.61% | 9.59% | -29.7% | 9.52% | -38.84% | 12.55% | -5.27% | 12.65% | 11.71% | 13.06% | 9.04% | 7.6% | -3.66% | 7.81% | 12.09% |
| Net Income Growth % | -485.02% | -1501.75% | -97.83% | -2.39% | 24.36% | 7.32% | 44.55% | 11.33% | 83.51% | -20.3% | 3.65% | 17.85% | 23.21% | 5.69% | -11.2% | 132.54% | -394.19% | 121.93% | -437.97% | 376.8% | -139.28% | 58.14% | 12.03% | 59.88% | 41.59% | 415.46% | -165.55% | -26.75% | - |
| Net Income (Continuing) | -182.88M | -142.16M | 25.29M | 480.37M | 492.61M | 398.84M | 365.31M | 254.06M | 227.22M | 125.59M | 156.09M | 152.04M | 129.92M | 105.42M | 102.12M | 115.52M | -334.11M | 109.38M | -522.27M | 158.02M | 126.83M | 147.63M | 91.37M | 80.15M | 50.13M | 35.41M | 17.88M | 17.12M | 23.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.51M | 0 | 280K | 0 | 0 | 0 | 0 | 0 | 0 | 3.22M | 424K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 47.72M | 46.56M | 46.58M | 62.12M | 47.21M | 57.17M | 29.07M | 31.89M | 20.97M | 18.94M | 17.02M | 32.5M | 32.14M | 23.67M | 2.4M | 1.78M | 1.3M | -1.42M | 422K | 3.5M | 9.22M | 9.72M | 9.79M | 10.18M | 18.57M | 12.99M | 13.33M | 304K | 306K |
| EPS (Diluted) | -3.77 | -2.91 | 0.20 | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 | 3.23 | 3.13 | 2.66 | 2.12 | 2.01 | 2.14 | -5.38 | 1.74 | -7.76 | 2.25 | -0.80 | 1.96 | 1.67 | 1.64 | 1.06 | 0.80 | -0.35 | 0.86 | 2.27 |
| EPS Growth % | -478.46% | -1555% | -97.83% | -2.74% | 24.74% | 5.56% | 42.01% | 9.74% | 81.89% | -21.36% | 3.19% | 17.67% | 25.47% | 5.47% | -6.07% | 139.78% | -409.2% | 122.42% | -444.89% | 381.25% | -140.82% | 17.37% | 1.83% | 54.72% | 32.5% | 328.57% | -140.7% | -62.11% | - |
| EPS (Basic) | - | -2.91 | 0.20 | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 | 3.21 | 2.72 | 2.15 | 2.03 | 2.16 | -5.38 | 1.75 | -7.76 | 2.31 | -0.81 | 2.04 | 1.81 | 1.76 | 1.12 | 0.86 | -0.40 | 0.86 | 2.27 |
| Diluted Shares Outstanding | 48.95M | 49.56M | 51.63M | 51.45M | 51.3M | 51.42M | 50.61M | 49.69M | 49.02M | 48.56M | 47.96M | 47.63M | 47.56M | 48.49M | 48.41M | 51.32M | 62.56M | 65.64M | 67.27M | 68.74M | 69.73M | 72.45M | 56.05M | 48.87M | 47.29M | 44.26M | 32.07M | 19.82M | 10.29M |
| Basic Shares Outstanding | 48.95M | 49.56M | 51.38M | 51.23M | 50.81M | 50.29M | 49.55M | 48.73M | 47.95M | 47.48M | 47.01M | 46.5M | 46.63M | 47.74M | 47.91M | 50.82M | 62.56M | 65.37M | 67.27M | 66.96M | 68.87M | 69.61M | 49.6M | 45.54M | 44.76M | 41.17M | 28.06M | 19.82M | 10.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 2.35% | 2.37% | 2.93% | 2.06% | - | - | - |
Biotech funding cycle sensitivity
As reported in recent financial filings, CRL's revenue growth has remained largely stagnant, with the most recent quarter showing a marginal 1.2% increase following a period of persistent contraction, suggesting that the company is struggling to find meaningful top-line momentum in the current biopharma R&D environment.
The inability to consistently grow revenue above low single digits indicates that the company's core preclinical services are highly sensitive to the broader biotech funding winter. Investors should monitor whether this trajectory reflects a structural loss of market share or merely a temporary deferral of project starts by cash-constrained early-stage clients.
Based on the provided income statement data, CRL's gross margin has experienced significant volatility, dropping from a peak of 35.9% in late 2023 to 28.0% in 2026Q1, which highlights the difficulty of maintaining profitability within a high-fixed-cost vivarium and laboratory testing infrastructure.
The erosion of gross margins suggests that the company is failing to achieve the necessary capacity utilization to offset rising labor and logistical costs. This margin contraction appears to be a primary driver of the recent bottom-line weakness, warranting further investigation into whether pricing power is being sacrificed to maintain volume.
According to the company's quarterly income statements, the divergence between operating income and net income, exemplified by the -$276.6M net loss in 2025Q4 despite positive operating income, indicates that non-operating items and potential asset impairments are significantly obscuring the underlying quality of reported earnings.
The recurring presence of large net losses in periods of positive operating performance suggests that the company is frequently absorbing significant non-cash charges or restructuring costs. Analysts should treat headline EPS figures with caution, as these adjustments may mask the true cash-generative capacity of the core preclinical business.
Financial data indicates that CRL's operating margin has fluctuated between -16.7% and 14.8% over the last ten quarters, raising serious questions about the sustainability of its current cost structure if revenue growth fails to accelerate in the coming fiscal periods.
Short-sellers may focus on the company's inability to protect operating margins during periods of revenue stagnation, which suggests a lack of operational leverage. If the company cannot rationalize its fixed-cost base, the risk of further margin compression remains high, potentially leading to continued volatility in shareholder value.
Quick answers to the most common questions about buying CRL stock.
For fiscal year 2025, Charles River Laboratories International, Inc. (CRL) reported total revenue of $4.02B. This represents a 1977.3% increase compared to $193.3M in 1998.
Charles River Laboratories International, Inc. (CRL) reported a net loss of $144.3M for the fiscal year ending 2025.
Charles River Laboratories International, Inc. (CRL) reported an operating income of $507.8M, resulting in an operating profit margin of 12.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Charles River Laboratories International, Inc. (CRL) generated $1.23B in gross profit for the year, representing a gross profit margin of 30.5%. This demonstrates the company's core pricing power and production efficiency.